JP2022522942A5 - - Google Patents
Info
- Publication number
- JP2022522942A5 JP2022522942A5 JP2021539428A JP2021539428A JP2022522942A5 JP 2022522942 A5 JP2022522942 A5 JP 2022522942A5 JP 2021539428 A JP2021539428 A JP 2021539428A JP 2021539428 A JP2021539428 A JP 2021539428A JP 2022522942 A5 JP2022522942 A5 JP 2022522942A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- tumor
- formula
- inflammation
- related disorder
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2024139639A JP7856707B2 (ja) | 2019-01-07 | 2024-08-21 | 有機化合物 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962789499P | 2019-01-07 | 2019-01-07 | |
| US62/789,499 | 2019-01-07 | ||
| PCT/US2020/012578 WO2020146384A1 (en) | 2019-01-07 | 2020-01-07 | Organic compounds |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024139639A Division JP7856707B2 (ja) | 2019-01-07 | 2024-08-21 | 有機化合物 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022522942A JP2022522942A (ja) | 2022-04-21 |
| JP2022522942A5 true JP2022522942A5 (cg-RX-API-DMAC10.html) | 2022-12-19 |
| JP7543278B2 JP7543278B2 (ja) | 2024-09-02 |
Family
ID=71520889
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021539428A Active JP7543278B2 (ja) | 2019-01-07 | 2020-01-07 | 有機化合物 |
| JP2024139639A Active JP7856707B2 (ja) | 2019-01-07 | 2024-08-21 | 有機化合物 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024139639A Active JP7856707B2 (ja) | 2019-01-07 | 2024-08-21 | 有機化合物 |
Country Status (4)
| Country | Link |
|---|---|
| US (2) | US12396992B2 (cg-RX-API-DMAC10.html) |
| EP (1) | EP3908285A4 (cg-RX-API-DMAC10.html) |
| JP (2) | JP7543278B2 (cg-RX-API-DMAC10.html) |
| WO (1) | WO2020146384A1 (cg-RX-API-DMAC10.html) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11291666B2 (en) | 2016-09-12 | 2022-04-05 | Intra-Cellular Therapies, Inc. | Uses |
| JP7493460B2 (ja) | 2018-05-25 | 2024-05-31 | イントラ－セルラー・セラピーズ・インコーポレイテッド | 有機化合物 |
| WO2020146384A1 (en) * | 2019-01-07 | 2020-07-16 | Intra-Cellular Therapies, Inc. | Organic compounds |
| US12599603B2 (en) | 2019-09-03 | 2026-04-14 | Intra-Cellular Therapies, Inc. | Methods of treatment |
| US12364695B2 (en) | 2020-06-02 | 2025-07-22 | Intra-Cellular Therapies, Inc. | Methods of treating inflammatory disease |
| MX2024010993A (es) * | 2022-03-11 | 2024-09-17 | Intra Cellular Therapies Inc | Compuestos organicos. |
Family Cites Families (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4690935A (en) | 1983-03-31 | 1987-09-01 | Wayne State University | Inhibition of tumor growth and metastasis with calcium channel blocker compounds |
| WO2006133261A2 (en) | 2005-06-06 | 2006-12-14 | Intra-Cellular Therapies, Inc. | Organic compounds |
| EP2939676A1 (en) | 2007-12-06 | 2015-11-04 | Intra-Cellular Therapies, Inc. | Organic compounds |
| EA201170769A1 (ru) | 2008-12-06 | 2012-02-28 | Интра-Селлулар Терапиз, Инк. | Органические соединения |
| AU2009322903A1 (en) | 2008-12-06 | 2010-06-10 | Intra-Cellular Therapies, Inc. | Organic compounds |
| US10695431B2 (en) | 2010-10-29 | 2020-06-30 | Infirst Healthcare Limited | Solid solution compositions and use in cardiovascular disease |
| WO2012177263A1 (en) | 2011-06-24 | 2012-12-27 | Intra-Cellular Therapies, Inc. | Compounds and methods of prophylaxis and treatment regarding nictonic receptor antagonists |
| JP6224597B2 (ja) | 2011-09-27 | 2017-11-01 | バイオメッド バレー ディスカバリーズ，インコーポレイティド | グリオーマを処置するための組成物及び方法 |
| WO2013138118A1 (en) | 2012-03-14 | 2013-09-19 | The Regents Of The University Of California | Treatment of inflammatory disorders in non-human mammals |
| US9499562B2 (en) | 2012-06-18 | 2016-11-22 | Dart Neuroscience (Cayman) Ltd. | Substituted thiophene- and furan-fused azolopyrimidine-5-(6H)-one compounds |
| DK2970279T3 (da) | 2013-03-15 | 2020-11-30 | Intra Cellular Therapies Inc | Organiske forbindelser |
| ES2717688T3 (es) | 2013-03-15 | 2019-06-24 | Intra Cellular Therapies Inc | Inhibidores de la PDE1 para uso en el tratamiento y/o prevención de lesiones de SNC, y enfermedades, trastornos o lesiones de SNP |
| JP6696904B2 (ja) * | 2014-01-08 | 2020-05-20 | イントラ−セルラー・セラピーズ・インコーポレイテッドＩｎｔｒａ−Ｃｅｌｌｕｌａｒ Ｔｈｅｒａｐｉｅｓ， Ｉｎｃ． | 製剤および医薬組成物 |
| DK3157926T3 (da) | 2014-06-20 | 2019-08-19 | Intra Cellular Therapies Inc | Organiske forbindelser |
| US10131671B2 (en) * | 2014-08-07 | 2018-11-20 | Intra-Cellular Therapies, Inc. | Organic compounds |
| CA2961212C (en) | 2014-09-17 | 2024-02-06 | Intra-Cellular Therapies, Inc. | Compounds and methods |
| US10849862B2 (en) | 2014-12-26 | 2020-12-01 | Theravalues Corporation | Formulation of curcumin and anti-PD-1 antibody |
| EP3288980B1 (en) * | 2015-04-28 | 2021-03-10 | Bristol-Myers Squibb Company | Treatment of pd-l1-positive melanoma using an anti-pd-1 antibody |
| CA2991628C (en) | 2015-07-16 | 2020-04-07 | Bioxcel Therapeutics, Inc. | A novel approach for treatment of cancer using immunomodulation |
| US11291666B2 (en) | 2016-09-12 | 2022-04-05 | Intra-Cellular Therapies, Inc. | Uses |
| MA46716A (fr) | 2016-11-03 | 2019-09-11 | Juno Therapeutics Inc | Polythérapie de thérapie cellulaire et d'inhibiteur de la microglie |
| CA3047579A1 (en) | 2016-12-22 | 2018-06-28 | Abbvie Inc. | Compositions and methods of enhancing or augmenting type i ifn production |
| AU2018325445A1 (en) | 2017-08-31 | 2020-03-19 | Abbvie Inc. | Ectonucleotide pyrophosphatase-phosphodiesterase 1 (ENPP-1) inhibitors and uses thereof |
| JP7493460B2 (ja) | 2018-05-25 | 2024-05-31 | イントラ－セルラー・セラピーズ・インコーポレイテッド | 有機化合物 |
| EP3856191A4 (en) | 2018-09-25 | 2022-06-22 | Intra-Cellular Therapies, Inc. | NOVEL USES |
| WO2020146384A1 (en) * | 2019-01-07 | 2020-07-16 | Intra-Cellular Therapies, Inc. | Organic compounds |
| US12599603B2 (en) | 2019-09-03 | 2026-04-14 | Intra-Cellular Therapies, Inc. | Methods of treatment |
| MX2024010993A (es) | 2022-03-11 | 2024-09-17 | Intra Cellular Therapies Inc | Compuestos organicos. |
-
2020
- 2020-01-07 WO PCT/US2020/012578 patent/WO2020146384A1/en not_active Ceased
- 2020-01-07 EP EP20738760.6A patent/EP3908285A4/en active Pending
- 2020-01-07 JP JP2021539428A patent/JP7543278B2/ja active Active
- 2020-01-07 US US17/421,303 patent/US12396992B2/en active Active
-
2024
- 2024-08-21 JP JP2024139639A patent/JP7856707B2/ja active Active
-
2025
- 2025-07-16 US US19/271,087 patent/US20250339438A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US11370763B2 (en) | Compounds and compositions for treating conditions associated with NLRP activity | |
| Li et al. | An ROS-responsive artesunate prodrug nanosystem co-delivers dexamethasone for rheumatoid arthritis treatment through the HIF-1α/NF-κB cascade regulation of ROS scavenging and macrophage repolarization | |
| US11801316B2 (en) | Cromolyn derivatives and related methods of imaging and treatment | |
| JP2008520740A (ja) | Ｖｅｇｆ産生を阻害する活性因子としての置換されたフェノール | |
| AU2005228685A1 (en) | Hydrazide-containing CFTR inhibitor compounds and uses thereof | |
| EA026674B1 (ru) | Соединения, применимые в качестве лекарственных средств | |
| JP2022546711A5 (cg-RX-API-DMAC10.html) | ||
| JP2016510764A (ja) | 混合系キナーゼ阻害剤および治療法 | |
| JP2004521866A (ja) | ニトロソジフェニルアミン誘導体 | |
| JP2020505356A5 (cg-RX-API-DMAC10.html) | ||
| KR20260047521A (ko) | 피리딘 유도체 및 이의 면역억제 관련 용도 | |
| US20230192626A1 (en) | Novel soluble epoxide hydrolase inhibitors and method of use thereof | |
| KR20150031481A (ko) | 단백질 응집 저해제로서의 디- 및 트리-헤테로아릴 유도체 | |
| JP2024502175A5 (cg-RX-API-DMAC10.html) | ||
| JP6159388B2 (ja) | タンパク質凝集の阻害剤としてのフェニル−尿素及びフェニル−カルバメート誘導体 | |
| EP1370250A2 (en) | Flt-1 ligands and their uses in the treatment of diseases regulatable by angiogenesis | |
| JP2025509446A5 (cg-RX-API-DMAC10.html) | ||
| JPWO2001036402A1 (ja) | 新規な２−（ｎ−シアノイミノ）チアゾリジン−４−オン誘導体 | |
| RU2006113942A (ru) | Производные бензимидазолона и хиназолина как ангонисты orl-рецепторов человека | |
| US20030096814A1 (en) | Isoxazolone compounds useful in treating diseases associated with unwanted cytokine activity | |
| US20040110757A1 (en) | Flt-1 ligands and their uses in the treatment of diseases regulatable by angiogenesis | |
| US6140362A (en) | Method for inhibiting the growth of mammalian cells | |
| CA2417282A1 (en) | Method of treating angiogenesis-related disorders using benzoyl phenylacetic acid | |
| JP2025003966A (ja) | キノンレダクターゼ２阻害剤化合物およびその使用 | |
| RU2007133712A (ru) | Способы улучшения распределения лекарственных средств |